Pharmacokinetic indices for cefovecin after single-dose administration to adult sea otters (Enhydra lutris)

E. A. Lee, Barbara A Byrne, M. A. Young, M. Murray, M. A. Miller, Lisa A Tell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Seven sea otters received a single subcutaneous dose of cefovecin at 8 mg/kg body weight. Plasma samples were collected at predetermined time points and assayed for total cefovecin concentrations using ultra-performance liquid chromatography and tandem mass spectrometry. The mean (±SD) noncompartmental pharmacokinetic indices were as follows: CMax (obs) 70.6 ± 14.6 μg/mL, TMax (obs) 2.9 ± 1.5 h, elimination rate constant (kel) 0.017 ± 0.002/h, elimination half-life (t1/2kel) 41.6 ± 4.7 h, area under the plasma concentration-vs.-time curve to last sample (AUClast) 3438.7 ± 437.7 h·μg/mL and AUC extrapolated to infinity (AUC0→∞) 3447.8 ± 439.0 h·μg/mL. The minimum inhibitory concentrations (MIC) for select isolates were determined and used to suggest possible dosing intervals of 10 days, 5 days, and 2.5 days for gram-positive, gram-negative, and Vibrio parahaemolyticus bacterial species, respectively. This study found a single subcutaneous dose of cefovecin sodium in sea otters to be clinically safe and a viable option for long-acting antimicrobial therapy. 2016 John Wiley & Sons Ltd.

Original languageEnglish (US)
JournalJournal of Veterinary Pharmacology and Therapeutics
DOIs
StateAccepted/In press - 2016

Fingerprint

cefovecin
Otters
Enhydra lutris
pharmacokinetics
Pharmacokinetics
dosage
Vibrio parahaemolyticus
ultra-performance liquid chromatography
Microbial Sensitivity Tests
minimum inhibitory concentration
Tandem Mass Spectrometry
Liquid Chromatography
drug therapy
half life
Area Under Curve
Half-Life
Sodium
Body Weight
sodium
sampling

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

@article{0a016b064a0d4b2abe9d32925b18924c,
title = "Pharmacokinetic indices for cefovecin after single-dose administration to adult sea otters (Enhydra lutris)",
abstract = "Seven sea otters received a single subcutaneous dose of cefovecin at 8 mg/kg body weight. Plasma samples were collected at predetermined time points and assayed for total cefovecin concentrations using ultra-performance liquid chromatography and tandem mass spectrometry. The mean (±SD) noncompartmental pharmacokinetic indices were as follows: CMax (obs) 70.6 ± 14.6 μg/mL, TMax (obs) 2.9 ± 1.5 h, elimination rate constant (kel) 0.017 ± 0.002/h, elimination half-life (t1/2kel) 41.6 ± 4.7 h, area under the plasma concentration-vs.-time curve to last sample (AUClast) 3438.7 ± 437.7 h·μg/mL and AUC extrapolated to infinity (AUC0→∞) 3447.8 ± 439.0 h·μg/mL. The minimum inhibitory concentrations (MIC) for select isolates were determined and used to suggest possible dosing intervals of 10 days, 5 days, and 2.5 days for gram-positive, gram-negative, and Vibrio parahaemolyticus bacterial species, respectively. This study found a single subcutaneous dose of cefovecin sodium in sea otters to be clinically safe and a viable option for long-acting antimicrobial therapy. 2016 John Wiley & Sons Ltd.",
author = "Lee, {E. A.} and Byrne, {Barbara A} and Young, {M. A.} and M. Murray and Miller, {M. A.} and Tell, {Lisa A}",
year = "2016",
doi = "10.1111/jvp.12322",
language = "English (US)",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Pharmacokinetic indices for cefovecin after single-dose administration to adult sea otters (Enhydra lutris)

AU - Lee, E. A.

AU - Byrne, Barbara A

AU - Young, M. A.

AU - Murray, M.

AU - Miller, M. A.

AU - Tell, Lisa A

PY - 2016

Y1 - 2016

N2 - Seven sea otters received a single subcutaneous dose of cefovecin at 8 mg/kg body weight. Plasma samples were collected at predetermined time points and assayed for total cefovecin concentrations using ultra-performance liquid chromatography and tandem mass spectrometry. The mean (±SD) noncompartmental pharmacokinetic indices were as follows: CMax (obs) 70.6 ± 14.6 μg/mL, TMax (obs) 2.9 ± 1.5 h, elimination rate constant (kel) 0.017 ± 0.002/h, elimination half-life (t1/2kel) 41.6 ± 4.7 h, area under the plasma concentration-vs.-time curve to last sample (AUClast) 3438.7 ± 437.7 h·μg/mL and AUC extrapolated to infinity (AUC0→∞) 3447.8 ± 439.0 h·μg/mL. The minimum inhibitory concentrations (MIC) for select isolates were determined and used to suggest possible dosing intervals of 10 days, 5 days, and 2.5 days for gram-positive, gram-negative, and Vibrio parahaemolyticus bacterial species, respectively. This study found a single subcutaneous dose of cefovecin sodium in sea otters to be clinically safe and a viable option for long-acting antimicrobial therapy. 2016 John Wiley & Sons Ltd.

AB - Seven sea otters received a single subcutaneous dose of cefovecin at 8 mg/kg body weight. Plasma samples were collected at predetermined time points and assayed for total cefovecin concentrations using ultra-performance liquid chromatography and tandem mass spectrometry. The mean (±SD) noncompartmental pharmacokinetic indices were as follows: CMax (obs) 70.6 ± 14.6 μg/mL, TMax (obs) 2.9 ± 1.5 h, elimination rate constant (kel) 0.017 ± 0.002/h, elimination half-life (t1/2kel) 41.6 ± 4.7 h, area under the plasma concentration-vs.-time curve to last sample (AUClast) 3438.7 ± 437.7 h·μg/mL and AUC extrapolated to infinity (AUC0→∞) 3447.8 ± 439.0 h·μg/mL. The minimum inhibitory concentrations (MIC) for select isolates were determined and used to suggest possible dosing intervals of 10 days, 5 days, and 2.5 days for gram-positive, gram-negative, and Vibrio parahaemolyticus bacterial species, respectively. This study found a single subcutaneous dose of cefovecin sodium in sea otters to be clinically safe and a viable option for long-acting antimicrobial therapy. 2016 John Wiley & Sons Ltd.

UR - http://www.scopus.com/inward/record.url?scp=84971432694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971432694&partnerID=8YFLogxK

U2 - 10.1111/jvp.12322

DO - 10.1111/jvp.12322

M3 - Article

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

ER -